Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

16
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
16
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

12
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
12
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.5K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.5K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

16
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
16
The Proteasome01:13

The Proteasome

1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Five-year Outcomes From a Career Exploration Pilot Program for Developmental & Behavioral Pediatrics.

Journal of developmental and behavioral pediatrics : JDBP·2026
Same author

Improving Health-Related Social Needs Screening and Support Across a Pediatric Health Care System.

Pediatrics·2026
Same author

Attention-Deficit/Hyperactivity Disorder and Disruptive Behavior in a Child With Eosinophilic Esophagitis and Failure to Thrive.

Journal of developmental and behavioral pediatrics : JDBP·2026
Same author

Systematic study of the structure and aggregation propensity of transthyretin under different pH conditions.

Journal of biomolecular structure & dynamics·2025
Same author

Attention-Deficit/Hyperactivity Disorder in Medication Treated Preschool-Age Children Without and With Autism Spectrum Disorder: A Developmental-Behavioral Research Network Study.

Journal of developmental and behavioral pediatrics : JDBP·2025
Same author

Demethoxycurcumin induces apoptosis and reduces cell migration by affecting AKT/mTOR-dependent autophagy in human glioma U87MG and T98G cell lines.

Molecular biology reports·2025

Related Experiment Video

Updated: Apr 23, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K

Ignored avenues in alpha-synuclein associated proteopathy.

Rimpy K Chowhan, Shruti Mittal, Tanveer A Dar

  • 1Dr. B.R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi, India. lairksingh@gmail.com.

CNS & Neurological Disorders Drug Targets
|September 18, 2014
PubMed
Summary

Parkinson's disease (PD) involves alpha-synuclein (αSyn) aggregation, a key factor in neuronal toxicity. Exploring unexplored therapeutic avenues, including αSyn modifications and associated diseases, may lead to novel combination therapies for PD.

More Related Videos

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

19.1K
Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

23.5K

Related Experiment Videos

Last Updated: Apr 23, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

19.1K
Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

23.5K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Alpha-synuclein (αSyn) aggregation is central to Parkinson's disease (PD) and other synucleopathies.
  • Mutations in αSyn are linked to increased PD risk, highlighting its inherent significance.
  • Current PD treatments offer symptomatic relief, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review unexplored therapeutic avenues for Parkinson's disease (PD).
  • To discuss the clinical implications of targeting alpha-synuclein (αSyn) modifications and associated health conditions.
  • To provide insights into novel therapeutic interventions by examining the interplay between PD and other diseases.

Main Methods:

  • Comprehensive review of existing literature on αSyn and PD.
  • Analysis of potential therapeutic targets including post-translational modifications and cellular small molecules.
  • Exploration of the links between PD and comorbid conditions like Gaucher's disease, cardiovascular disorders, and diabetes.

Main Results:

  • Identified unexplored avenues such as αSyn modifications and the influence of cellular molecules on aggregation.
  • Highlighted the potential of targeting these overlooked areas for combinational PD therapy.
  • Reviewed the intricate relationship between PD and various other health conditions, offering new perspectives.

Conclusions:

  • Targeting unexplored aspects of alpha-synuclein (αSyn) biology and its interplay with other diseases offers promising avenues for Parkinson's disease (PD) treatment.
  • Further research into post-translational modifications, cellular small molecules, and associated health conditions is crucial for developing effective combinational therapies.
  • A holistic approach considering the multifaceted nature of PD pathophysiology is essential for future therapeutic advancements.